Brief: Elicera Therapeutics Enters Agreement With BionNTech
Nov 9 (Reuters) - Elicera Therapeutics AB ELIC.ST :
* ELICERA THERAPEUTICS ENTERS AGREEMENT WITH BIONTECH FOR
CONTRACT
MANUFACTURING OF VIRAL VECTORS FOR CAR T-CELL THERAPY
* WE EXPECT TO HAVE COMPLETED PRODUCTION OF VIRAL VECTORS BY
SECOND HALF OF 2022 AND THAT WE CAN START TREATING PATIENTS WITH
ELC-401 BY SECOND HALF OF 2023
Source text for Eikon: ID:nWkrPR5T0
Further company coverage: ELIC.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Elicera Therapeutics AB
See all newsBrief: Elicera Therapeutics Completes Phase I Part Of Carma Study
Brief: Elicera Therapeutics Gets Medical Products Agency Approval To Advance CARMA Study
Brief: Elicera Gets Clearance To Use Highest ELC-301 Dose Ahead Of Phase IIa
Brief: Elicera Gets First Patent Allowance For ELC-201
Brief: Elicera Receives Notice Of Allowance For U.S. Patent Application